Workflow
Novartis(NVS)
icon
Search documents
Novartis(NVS) - 2023 Q3 - Earnings Call Transcript
2023-10-24 17:55
Operator Thank you. Your next question comes from the line of Florent Cespedes from Societe Generale. Please go ahead. Florent Cespedes Good afternoon. Thank you very much for taking my question. On emerging market, you delivered pretty consistent growth quarter-over-quarter. I was just wondering, how confident are you to continue to deliver such growth? Or is there any loss of exclusivity to come in certain countries, notably in China that could impact this growth trajectory? Thank you. Yeah. Thanks, Flore ...
Shareholder Analyst Call
2023-10-24 15:01
Insights PSMAfore trial design BPI-SF pain intensity scale2 HR: 0.69 (95% CI: 0.56, 0.85) Novartis Investor Relations Investor Presentation October 24, 2023 This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as "potential," "will," "planned," "pipeline," "outlook," or similar expressions, or by express or implied discussions regarding potential marketing approvals, new ...
Novartis(NVS) - 2023 Q3 - Earnings Call Presentation
2023-10-24 13:21
ianalumab - BAFF-R inhibitor Primary Outcome Measures | --- | --- | --- | --- | --- | --- | |---------------------------------------------------------------|---------------------------------------------|---------------------------|-----------------------------------------------------------|-----------------------------|-------| | Company overview Company overview | Financial review Financial review | Conclusions Conclusions | Appendix Appendix | References References | | | Innovation: Pipeline overview Inno ...
Novartis AG (NVS) Shareholder Analyst Call (Transcript)
2023-10-24 03:09
https://reportify-1252068037.cos.ap-beijing.myqcloud.com/media/production/seek_media_content_6b2d9291fffba185fd255dda28ed2961.html ...
诺华制药(NVS) - 2023 Q3 - Quarterly Report
2023-10-23 16:00
Novartis Third Quarter and Nine Months 2023 Condensed Interim Financial Report – Supplementary Data | INDEX | Page | | --- | --- | | COMPANY OPERATING PERFORMANCE REVIEW | | | Continuing operations | 3 | | Discontinued operations | 11 | | Total Company | 11 | | COMPANY CASH FLOW AND BALANCE SHEET | 12 | | INNOVATION REVIEW | 16 | | CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS | | | Consolidated income statements | 19 | | Consolidated statements of comprehensive income | 21 | | Consolidated balance sh ...
Novartis(NVS) - 2023 Q2 - Earnings Call Transcript
2023-07-18 17:13
Novartis AG (NYSE:NVS) Q2 2023 Earnings Conference Call July 18, 2023 8:00 AM ET Company Participants | --- | --- | |------------------------------------------------------------------------------------------------------------------------------|-------| | | | | Samir Shah - Global Head, Investor Relations Vas Narasimhan - Chief Executive Officer Harry Kirsch - Chief Financial Officer | | | Conference Call Participants | | | Richard Vosser - JPMorgan | | | Jo Walton - Credit Suisse | | | Emmanuel Papadakis - ...
诺华制药(NVS) - 2023 Q2 - Quarterly Report
2023-07-17 16:00
Novartis Second Quarter and Half Year 2023 Condensed Interim Financial Report – Supplementary Data | INDEX | Page | | --- | --- | | GROUP AND DIVISIONAL OPERATING PERFORMANCE | | | Group | 3 | | Innovative Medicines | 7 | | Sandoz | 13 | | CASH FLOW AND GROUP BALANCE SHEET | 15 | | INNOVATION REVIEW | 18 | | CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS | | | Consolidated income statements | 21 | | Consolidated statements of comprehensive income | 23 | | Consolidated balance sheets | 24 | | Consolidat ...
Novartis(NVS) - 2023 Q1 - Earnings Call Transcript
2023-04-25 14:47
Andrew Baum Thank you. Please forgive the voice. I'm struggling with COVID. A question for Vas, I suspect you remember, historically, I've described the bases is suffering from [indiscernible] syndrome in always being the early adopter and taking unnecessary risk relative to peers. IÂ'm going to completely contradict myself. The early data from SET with RT CD19 in refractory autoimmune is remarkable. The biology is strong, patient access node patients is much easier in oncology. We understand that Bristol i ...
Novartis(NVS) - 2023 Q1 - Earnings Call Presentation
2023-04-25 12:21
eBC – early breast cancer. ET – endocrine therapy. iDFS – invasive disease-free survival. 1. Unprobabilized peak sales. 2. Under stage II: N0, T0N1 is excluded; T2N0 only if G3, or G2 with Ki67≥20% or high risk on Oncotype DX / Prosigna / MammaPrint / EndoPredict. 3. Estimated incidence US + EU5. Sources: DRG (US) and Kantar (EU5). TNM and grade information based on SEER AJCC 8th Incidence Report. 9 NOVARTIS Q1 RESULTS | APRIL 25, 2023 | NOVARTIS INVESTOR PRESENTATION APPOINT-PNH: Single-arm Ph3 trial in ad ...
Novartis(NVS) - 2022 Q4 - Earnings Call Transcript
2023-02-01 15:15
Novartis AG (NYSE:NVS) Q4 2022 Earnings Conference Call February 1, 2023 8:00 AM ET Company Participants Samir Shah - Global Head of Investor Relations Vasant Narasimhan - Chief Executive Officer Harry Kirsch - Chief Financial Officer Conference Call Participants Matthew Weston - Credit Suisse Graham Parry - Bank of America Stephen Scala - Cowen Tim Anderson - Wolfe Research Florent Cespedes - Société Générale Peter Welford - Jefferies Seamus Fernandez - Guggenheim Securities Andrew Baum - Citi Keyur Parekh ...